Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HYDIN pseudogene 1 (HYDINP1) is classified as a pseudogene, meaning it is a DNA sequence similar to a known gene (in this case, HYDIN) but is non-functional and does not encode a protein[5]. It is not a receptor, enzyme, transporter, or other actionable therapeutic target. Pseudogenes can sometimes be transcriptionally active or have regulatory roles but are generally not considered therapeutically relevant molecular targets; current databases and genetic resources do not associate HYDINP1 with any known protein product, drug interactions, or roles in disease. The functional HYDIN gene, in contrast, encodes a ciliary protein associated with primary ciliary dyskinesia; HYDINP1 is unrelated to this pathology other than sharing homology[1][2][3][5]. There is no evidence for pharmacological targeting, validated biomarkers, or disease implication for HYDINP1. The principal issue with queries about this molecule as a receptor or therapeutic target is that it is a pseudogene and not a functional gene product[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HYDIN pseudogene 1 (HYDINP1).